JP2016508725A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016508725A5 JP2016508725A5 JP2015558946A JP2015558946A JP2016508725A5 JP 2016508725 A5 JP2016508725 A5 JP 2016508725A5 JP 2015558946 A JP2015558946 A JP 2015558946A JP 2015558946 A JP2015558946 A JP 2015558946A JP 2016508725 A5 JP2016508725 A5 JP 2016508725A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence
- nucleic acid
- acid molecule
- isolated nucleic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000007523 nucleic acids Chemical class 0.000 claims 36
- 108020004707 nucleic acids Proteins 0.000 claims 29
- 125000003275 alpha amino acid group Chemical group 0.000 claims 20
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 14
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 10
- 230000004068 intracellular signaling Effects 0.000 claims 8
- 229920001850 Nucleic acid sequence Polymers 0.000 claims 7
- 229920000160 (ribonucleotides)n+m Polymers 0.000 claims 5
- 230000011664 signaling Effects 0.000 claims 5
- 241000124008 Mammalia Species 0.000 claims 4
- 230000000139 costimulatory Effects 0.000 claims 4
- -1 CD3ε Proteins 0.000 claims 3
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102100019461 CD28 Human genes 0.000 claims 2
- 101700033362 CD28 Proteins 0.000 claims 2
- 206010014967 Ependymoma Diseases 0.000 claims 2
- 102100001475 ITGB2 Human genes 0.000 claims 2
- 101710040448 TNFRSF4 Proteins 0.000 claims 2
- 102100013135 TNFRSF4 Human genes 0.000 claims 2
- 201000008271 atypical teratoid rhabdoid tumor Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 201000010915 glioblastoma multiforme Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 206010002224 Anaplastic astrocytoma Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 102100000189 CD22 Human genes 0.000 claims 1
- 101700020617 CD22 Proteins 0.000 claims 1
- 102100019459 CD27 Human genes 0.000 claims 1
- 101700056583 CD27 Proteins 0.000 claims 1
- 102100016493 CD33 Human genes 0.000 claims 1
- 101700017647 CD33 Proteins 0.000 claims 1
- 102100016530 CD37 Human genes 0.000 claims 1
- 101700044364 CD37 Proteins 0.000 claims 1
- 102100013077 CD4 Human genes 0.000 claims 1
- 101700022938 CD4 Proteins 0.000 claims 1
- 102100005828 CD5 Human genes 0.000 claims 1
- 101700066525 CD5 Proteins 0.000 claims 1
- 102100019451 CD80 Human genes 0.000 claims 1
- 101700080477 CD80 Proteins 0.000 claims 1
- 102100008191 CD8A Human genes 0.000 claims 1
- 101700054655 CD8A Proteins 0.000 claims 1
- 102100016531 CD9 Human genes 0.000 claims 1
- 101700017162 CD9 Proteins 0.000 claims 1
- 102100015540 FCGR1A Human genes 0.000 claims 1
- 101710003440 FCGR1A Proteins 0.000 claims 1
- 102100015541 FCGR3A Human genes 0.000 claims 1
- 101710044656 FCGR3A Proteins 0.000 claims 1
- 101710044657 FCGR3B Proteins 0.000 claims 1
- 208000002409 Gliosarcoma Diseases 0.000 claims 1
- 102100004115 ICAM1 Human genes 0.000 claims 1
- 102100019442 ITGAL Human genes 0.000 claims 1
- 101710006573 ITGAL Proteins 0.000 claims 1
- 101710006663 ITGB2 Proteins 0.000 claims 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 claims 1
- 208000000172 Medulloblastoma Diseases 0.000 claims 1
- 206010027476 Metastasis Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 claims 1
- 108009000071 Non-small cell lung cancer Proteins 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 102100005499 PTPRC Human genes 0.000 claims 1
- 101700059076 PTPRC Proteins 0.000 claims 1
- 206010050487 Pinealoblastoma Diseases 0.000 claims 1
- 229920000795 Polyadenylation Polymers 0.000 claims 1
- 208000003991 Primitive Neuroectodermal Tumors Diseases 0.000 claims 1
- 206010057846 Primitive neuroectodermal tumour Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 108020004412 RNA 3' Polyadenylation Signals Proteins 0.000 claims 1
- 108091008153 T cell receptors Proteins 0.000 claims 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 1
- 229920000401 Three prime untranslated region Polymers 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000000259 anti-tumor Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 201000009030 carcinoma Diseases 0.000 claims 1
- 201000007369 choroid plexus cancer Diseases 0.000 claims 1
- 201000011231 colorectal cancer Diseases 0.000 claims 1
- 230000000295 complement Effects 0.000 claims 1
- 230000004940 costimulation Effects 0.000 claims 1
- 229920003013 deoxyribonucleic acid Polymers 0.000 claims 1
- 201000011610 giant cell glioblastoma Diseases 0.000 claims 1
- 201000011626 grade III astrocytoma Diseases 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 201000003113 pineoblastoma Diseases 0.000 claims 1
- 230000001177 retroviral Effects 0.000 claims 1
- 230000002463 transducing Effects 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Claims (49)
- キメラ抗原受容体(CAR)をコードする単離核酸分子であって、該CARが抗EGFRvIII結合ドメイン、膜貫通ドメインおよび、一次シグナル伝達ドメインを含む細胞内シグナル伝達ドメインを含み、該抗EGFRvIII結合ドメインが表2または配列番号11に示す任意の抗EGFRvIII軽鎖結合ドメインアミノ酸配列の軽鎖相補決定領域1 (LC CDR1)、軽鎖相補決定領域2 (LC CDR2)および軽鎖相補決定領域3 (LC CDR3)の1つ以上、ならびに表2または配列番号11に示す任意の抗EGFRvIII重鎖結合ドメインアミノ酸配列の重鎖相補決定領域1 (HC CDR1)、重鎖相補決定領域2 (HC CDR2)および重鎖相補決定領域3 (HC CDR3)の1つ以上を含む、単離核酸分子。
- （ａ）表2または配列番号11に示す任意の抗EGFRvIII軽鎖結合ドメインアミノ酸配列のLC CDR1、LC CDR2およびLC CDR3；（ｂ）表2または配列番号11に示す任意の抗EGFRvIII重鎖結合ドメインアミノ酸配列のHC CDR1、HC CDR2およびHC CDR3；または（ｃ）表2または配列番号11に示す任意の抗EGFRvIII軽鎖結合ドメインアミノ酸配列のLC CDR1、LC CDR2およびLC CDR3ならびに表2または配列番号11に示す任意の抗EGFRvIII重鎖結合ドメインアミノ酸配列のHC CDR1、HC CDR2およびHC CDR3を含む、請求項１記載の単離核酸分子。
- （ａ）表2または配列番号11に示す任意の軽鎖可変領域；（ｂ）表2または配列番号11に示す任意の重鎖可変領域；または（ｃ）表2または配列番号11に示す任意の軽鎖可変領域および表2または配列番号11に示す任意の重鎖可変領域を含む、請求項１記載の単離核酸分子。
- EGFRvIII結合ドメインがscFvである、請求項１〜３のいずれか一項に記載の単離核酸分子。
- （ａ）軽鎖可変領域が、表2または配列番号11に記載の軽鎖可変領域のアミノ酸配列に少なくとも1個、2個または3個の変更を有するが、30個以下、20個以下または10個以下の変更を有するアミノ酸配列か、または表2または配列番号11に示すアミノ酸配列と95〜99%の同一性を有する配列を含む；（ｂ）重鎖可変領域が、表2または配列番号11に記載の重鎖可変領域のアミノ酸配列に少なくとも1個、2個または3個の変更を有するが、30個以下、20個以下または10個以下の変更を有するアミノ酸配列か、または表2または配列番号11に示すアミノ酸配列と95〜99%の同一性を有する配列を含む；あるいは（ｃ）（ａ）および（ｂ）の両方である、請求項１〜４のいずれか一項に記載の単離核酸分子。
- 該抗EGFRvIII結合ドメインが、配列番号38、配列番号44、配列番号50、配列番号56、配列番号62、配列番号68、配列番号74、配列番号80および配列番号86からなる群から選択される配列または、それと95〜99%の同一性を有する配列を含む、請求項１〜５のいずれか一項に記載の単離核酸分子。
- 該抗EGFRvIII結合ドメインをコードする核酸配列が、配列番号39、配列番号45、配列番号51、配列番号57、配列番号63、配列番号69、配列番号75、配列番号81 および配列番号98からなる群から選択される配列または、それと95〜99%の同一性を有する配列を含む、請求項１〜６のいずれか一項に記載の単離核酸分子。
- コードされたCARが、T細胞受容体のα鎖、β鎖またはζ鎖、CD28、CD3ε、CD45、CD4、CD5、CD8、CD9、CD16、CD22、CD33、CD37、CD64、CD80、CD86、CD134、CD137およびCD154からなる群から選択されるタンパク質の膜貫通ドメインを含む膜貫通ドメインを含む、請求項１〜７のいずれか一項に記載の単離核酸分子。
- コードされた膜貫通ドメインが、配列番号15の配列、あるいは配列番号15のアミノ酸配列に少なくとも1個、2個または3個の変更を有するが、20個以下、10個以下または5個以下の変更を有するアミノ酸配列か、または配列番号15のアミノ酸配列と95〜99%の同一性を有する配列を含む、請求項１〜８のいずれか一項に記載の単離核酸分子。
- 膜貫通ドメインをコードする核酸配列が、配列番号8の配列またはそれと95〜99%の同一性を有する配列を含む、請求項１〜９のいずれか一項に記載の単離核酸分子。
- コードされた抗EGFRvIII結合ドメインが、ヒンジ領域によって膜貫通ドメインに結合している、請求項１〜１０のいずれか一項に記載の単離核酸分子。
- コードされたヒンジ領域が、配列番号14またはそれと95〜99%の同一性を有する配列を含む、請求項１１記載の単離核酸分子。
- ヒンジ領域をコードする核酸配列が、配列番号7の配列またはそれと95〜99%の同一性を有する配列を含む、請求項１１記載の単離核酸分子。
- 同時刺激ドメインをコードする配列をさらに含む、請求項１〜１３のいずれか一項に記載の単離核酸分子。
- コードされた同時刺激ドメインが、OX40、CD27、CD28、CDS、ICAM-1、LFA-1 (CD11a/CD18)、ICOS (CD278)および4-1BB (CD137)からなる群から選択されるタンパク質の機能性シグナル伝達ドメインを含む、請求項１４記載の単離核酸分子。
- コードされた同時刺激ドメインが、配列番号16の配列、あるいは配列番号16のアミノ酸配列に少なくとも1個、2個または3個の変更を有するが、20個以下、10個以下または5個以下の変更を有するアミノ酸配列か、または配列番号16のアミノ酸配列と95〜99%の同一性を有する配列を含む、請求項１４または１５記載の該単離核酸分子。
- 同時刺激ドメインをコードする核酸配列が、配列番号9の配列またはそれと95〜99%の同一性を有する配列を含む、請求項１４または１５記載の単離核酸分子。
- コードされた細胞内シグナル伝達ドメインが4-1BBの機能性シグナル伝達ドメインおよびCD3ζの機能性シグナル伝達ドメインを含む、請求項１〜１７のいずれか一項に記載の単離核酸分子。
- コードされた細胞内シグナル伝達ドメインが、配列番号16の配列および/または配列番号17または配列番号99の配列、あるいは配列番号16の配列および/または配列番号17または配列番号99のアミノ酸配列に少なくとも1個、2個または3個の変更を有するが、20個以下、10個以下または5個以下の変更を有するアミノ酸配列か、または配列番号16の配列および/または配列番号17または配列番号99のアミノ酸配列と95〜99%の同一性を有する配列を含む、請求項１〜１８のいずれか一項に記載の単離核酸分子。
- 該コードされた細胞内シグナル伝達ドメインが、配列番号16の配列および、配列番号17または配列番号99の配列を含む、該細胞内シグナル伝達ドメインを含む配列が同一フレーム内で、単一のポリペプチド鎖として発現する、請求項１〜１９のいずれか一項に記載の単離核酸分子。
- 該細胞内シグナル伝達ドメインをコードする核酸配列が、配列番号9の配列またはそれと95〜99%の同一性を有する配列および/または配列番号10または配列番号100の配列またはそれと95〜99%の同一性を有する配列を含む、請求項１〜２０のいずれか一項に記載の単離核酸分子。
- リーダー配列をさらに含む、請求項１〜２１のいずれか一項に記載の単離核酸分子。
- リーダー配列が、配列番号13を含む、請求項２２記載の単離核酸分子。
- 請求項１〜２３のいずれか一項に記載の核酸分子によりコードされている単離ポリペプチド分子。
- 配列番号43、配列番号49、配列番号55、配列番号61、配列番号67、配列番号73、配列番号79、配列番号85および配列番号90からなる群から選択される配列またはそれと95〜99%の同一性を有する配列を含む、請求項２４記載の単離ポリペプチド分子。
- 抗EGFRvIII結合ドメイン、膜貫通ドメインおよび細胞内シグナル伝達ドメインを含む、単離キメラ抗原受容体(CAR)分子。
- 該細胞内シグナル伝達ドメインが同時刺激ドメインおよび一次シグナル伝達ドメインを含む、請求項２６記載の単離CAR分子。
- 該抗EGFRvIII結合ドメインが、表2または配列番号11に示す任意の抗EGFRvIII結合ドメインの軽鎖相補決定領域1 (LC CDR1)、軽鎖相補決定領域2 (LC CDR2)および軽鎖相補決定領域3 (LC CDR3)の1つ以上ならびに、表2または配列番号11に示す任意の抗EGFRvIII結合ドメインの重鎖相補決定領域 1 (HC CDR1)、重鎖相補決定領域2 (HC CDR2)および重鎖相補決定領域3 (HC CDR3) の1つ以上を含む、請求項２６または２７記載の単離CAR分子。
- 該抗EGFRvIII結合ドメインがヒンジ領域によって膜貫通ドメインに結合している、請求項２６〜２８のいずれか一項に記載の単離CAR分子。
- リーダー配列をさらに含む、請求項２６〜２９のいずれか一項に記載の単離CAR分子。
- 配列番号38、44、50、56、62、68、74または80に示す抗EGFRvIII結合ドメインの軽鎖相補決定領域1 (LC CDR1)、軽鎖相補決定領域2 (LC CDR2)および軽鎖相補決定領域3 (LC CDR3)の1つ以上ならびに、配列番号38、44、50、56、62、68、74または80に示す抗EGFRvIII結合ドメインの重鎖相補決定領域1 (HC CDR1)、重鎖相補決定領域2 (HC CDR2)および重鎖相補決定領域3 (HC CDR3)の1つ以上を含む、抗EGFRvIII結合ドメイン。
- 配列番号38、配列番号44、配列番号50、配列番号56、配列番号62、配列番号68、配列番号74、配列番号80および配列番号86からなる群から選択される配列またはそれと95〜99%の同一性を有する配列を含む、請求項３１記載の抗EGFRvIII結合ドメイン。
- 請求項１〜２３のいずれか一項に記載の核酸分子を含む、ベクター。
- DNA、RNA、プラスミド、レンチウイルスベクター、アデノウイルスベクターおよびレトロウイルスベクターからなる群から選択される、請求項３３記載のベクター。
- プロモーターをさらに含む、請求項３３または３４記載のベクター。
- 該プロモーターがEF-1プロモーターである、請求項３５記載のベクター。
- 該EF-1プロモーターが配列番号97の配列を含む、請求項３６記載のベクター。
- 該ベクターが試験管内で転写されたベクターである、請求項３３〜３７のいずれか記載のベクター。
- ベクター中の核酸配列がさらにポリ(A)テールを含む、請求項３３〜３８のいずれか記載のベクター。
- ベクター中の核酸配列がさらに3’UTRを含む、請求項３３〜３９のいずれか記載のベクター。
- 請求項３３〜４０のいずれか記載のベクターを含む細胞。
- T細胞である、請求項４１記載の細胞。
- 該T細胞がCD8+ T細胞である、請求項４２記載の細胞。
- ヒト細胞である、請求項４１または４２記載の細胞。
- 請求項３３〜４０のいずれか一項に記載のベクターでT細胞に形質導入することを含む、細胞の作製方法。
- 試験管内で転写されたRNAまたは合成RNAを細胞に導入することを含む、RNA操作細胞集団の作製方法であって、該RNAが請求項１〜２３のいずれか一項に記載の核酸分子を含む、方法。
- 請求項４１〜４４のいずれか一項に記載の細胞を有効量で哺乳動物に投与することを含む、哺乳動物に抗腫瘍免疫を提供する方法。
- EGFRvIIIの発現に関連する疾患に罹患している哺乳動物の処置方法であって、該哺乳動物に、請求項４１〜４４のいずれか一項に記載の細胞を有効量で投与することを含む、方法。
- EGFRvIIIの発現に関連する疾患が、多形神経膠芽腫 (GBM)、未分化星状細胞腫、巨細胞神経膠芽腫、膠肉腫、未分化乏突起神経膠腫、未分化上衣腫、脈絡叢がん、未分化神経節膠腫、松果体芽腫、髄上皮腫、上衣芽腫、髄芽腫、テント上原始神経外胚葉性腫瘍、AT/RT(非定型奇形腫様/ラブドイド腫瘍)、肺がん(例えば非小細胞肺がん)、乳がん、前立腺がん、卵巣がん、結腸直腸がんおよび膀胱がんからなる群から選択されるがんまたはその任意の組合せ、または任意のがんの転移である、請求項４８記載の方法。
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361767071P | 2013-02-20 | 2013-02-20 | |
| US61/767,071 | 2013-02-20 | ||
| US201361888255P | 2013-10-08 | 2013-10-08 | |
| US61/888,255 | 2013-10-08 | ||
| PCT/US2014/017364 WO2014130657A1 (en) | 2013-02-20 | 2014-02-20 | Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019214013A Division JP7189860B2 (ja) | 2013-02-20 | 2019-11-27 | ヒト化抗ＥＧＦＲｖＩＩＩキメラ抗原受容体を用いたがんの処置 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016508725A JP2016508725A (ja) | 2016-03-24 |
| JP2016508725A5 true JP2016508725A5 (ja) | 2017-03-23 |
| JP6647868B2 JP6647868B2 (ja) | 2020-02-14 |
Family
ID=50389483
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015558946A Active JP6647868B2 (ja) | 2013-02-20 | 2014-02-20 | ヒト化抗ＥＧＦＲｖＩＩＩキメラ抗原受容体を用いたがんの処置 |
| JP2019214013A Active JP7189860B2 (ja) | 2013-02-20 | 2019-11-27 | ヒト化抗ＥＧＦＲｖＩＩＩキメラ抗原受容体を用いたがんの処置 |
| JP2022148492A Pending JP2022191241A (ja) | 2013-02-20 | 2022-09-16 | ヒト化抗ＥＧＦＲｖＩＩＩキメラ抗原受容体を用いたがんの処置 |
| JP2024102953A Pending JP2024129069A (ja) | 2013-02-20 | 2024-06-26 | ヒト化抗ＥＧＦＲｖＩＩＩキメラ抗原受容体を用いたがんの処置 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019214013A Active JP7189860B2 (ja) | 2013-02-20 | 2019-11-27 | ヒト化抗ＥＧＦＲｖＩＩＩキメラ抗原受容体を用いたがんの処置 |
| JP2022148492A Pending JP2022191241A (ja) | 2013-02-20 | 2022-09-16 | ヒト化抗ＥＧＦＲｖＩＩＩキメラ抗原受容体を用いたがんの処置 |
| JP2024102953A Pending JP2024129069A (ja) | 2013-02-20 | 2024-06-26 | ヒト化抗ＥＧＦＲｖＩＩＩキメラ抗原受容体を用いたがんの処置 |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US9394368B2 (ja) |
| EP (2) | EP2958943B1 (ja) |
| JP (4) | JP6647868B2 (ja) |
| KR (3) | KR102313997B1 (ja) |
| CN (2) | CN105358576B (ja) |
| AU (2) | AU2014218976B2 (ja) |
| BR (1) | BR112015019603A2 (ja) |
| CA (1) | CA2901960C (ja) |
| DK (1) | DK2958943T3 (ja) |
| ES (1) | ES2760023T3 (ja) |
| HK (1) | HK1217498A1 (ja) |
| HU (1) | HUE046961T2 (ja) |
| IL (1) | IL240335B (ja) |
| LT (1) | LT2958943T (ja) |
| MX (1) | MX2015010836A (ja) |
| MY (1) | MY190711A (ja) |
| PL (1) | PL2958943T3 (ja) |
| PT (1) | PT2958943T (ja) |
| RU (2) | RU2708032C2 (ja) |
| SG (1) | SG11201505896YA (ja) |
| WO (1) | WO2014130657A1 (ja) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7340638B2 (ja) | 2016-06-27 | 2023-09-07 | ジュノー セラピューティクス インコーポレイテッド | Ｍｈｃ－ｅ拘束性エピトープ、結合分子ならびに関連する方法および使用 |
Families Citing this family (205)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015513399A (ja) * | 2012-02-22 | 2015-05-14 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 癌の治療のために有用なｔ細胞の存続的集団を作製するための組成物および方法 |
| US9573988B2 (en) | 2013-02-20 | 2017-02-21 | Novartis Ag | Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells |
| WO2014130657A1 (en) | 2013-02-20 | 2014-08-28 | The Trustees Of The University Of Pennsylvania | Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor |
| WO2014145252A2 (en) | 2013-03-15 | 2014-09-18 | Milone Michael C | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| TWI654206B (zh) | 2013-03-16 | 2019-03-21 | 諾華公司 | 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症 |
| US10676528B2 (en) | 2013-12-06 | 2020-06-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Thymic stromal lymphopoietin receptor-specific chimeric antigen receptors and methods using same |
| CN116478927A (zh) | 2013-12-19 | 2023-07-25 | 诺华股份有限公司 | 人间皮素嵌合抗原受体及其用途 |
| JP6793902B2 (ja) | 2013-12-20 | 2020-12-02 | ノバルティス アーゲー | 調節可能キメラ抗原受容体 |
| WO2015112626A1 (en) * | 2014-01-21 | 2015-07-30 | June Carl H | Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules |
| WO2015120187A1 (en) | 2014-02-05 | 2015-08-13 | The University Of Chicago | Chimeric antigen receptors recognizing cancer-spevific tn glycopeptide variants |
| US10934346B2 (en) * | 2014-02-14 | 2021-03-02 | Bellicum Pharmaceuticals, Inc. | Modified T cell comprising a polynucleotide encoding an inducible stimulating molecule comprising MyD88, CD40 and FKBP12 |
| TW202330606A (zh) | 2014-03-21 | 2023-08-01 | 美商艾伯維有限公司 | 抗-egfr抗體及抗體藥物結合物 |
| IL293603B2 (en) | 2014-04-07 | 2024-03-01 | Novartis Ag | Cancer treatment using chimeric antigen receptor (CAR) against CD19 |
| BR112017001242A2 (pt) | 2014-07-21 | 2017-12-05 | Novartis Ag | tratamento de câncer usando um receptor antigênico quimérico a cd33 |
| CN106687483B (zh) | 2014-07-21 | 2020-12-04 | 诺华股份有限公司 | 使用人源化抗-bcma嵌合抗原受体治疗癌症 |
| MX2017001013A (es) | 2014-07-21 | 2018-02-21 | Novartis Ag | Tratamiento de cáncer usando un receptor quimérico de antígeno cll-1. |
| WO2016014553A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
| CN107074973A (zh) * | 2014-07-29 | 2017-08-18 | 辉瑞大药厂 | 用于癌症免疫疗法的EGFRvIII特异性嵌合抗原受体 |
| ES2781175T3 (es) | 2014-07-31 | 2020-08-31 | Novartis Ag | Subconjunto optimizado de células T que contienen un receptor de antígeno quimérico |
| CA2958553A1 (en) | 2014-08-19 | 2016-02-25 | Novartis Ag | Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment |
| RU2764074C2 (ru) | 2014-08-28 | 2022-01-13 | Байоатла, Ллк | Условно активные химерные антигенные рецепторы для модифицированных т-клеток |
| US11111288B2 (en) | 2014-08-28 | 2021-09-07 | Bioatla, Inc. | Conditionally active chimeric antigen receptors for modified t-cells |
| JP6868554B2 (ja) | 2014-09-02 | 2021-05-12 | ベリカム ファーマシューティカルズ， インコーポレイテッド | ＭｙＤ８８およびＣＤ４０ポリペプチドによるキメラ抗原受容体の共刺激 |
| ES2777305T3 (es) | 2014-09-04 | 2020-08-04 | Cellectis | Receptores de antígeno quiméricos específicos de la glicoproteína trofoblástica (5T4, TPBG) para inmunoterapia contra el cáncer |
| US10577417B2 (en) | 2014-09-17 | 2020-03-03 | Novartis Ag | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| WO2016057705A1 (en) | 2014-10-08 | 2016-04-14 | Novartis Ag | Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof |
| AU2015374296B2 (en) | 2014-12-29 | 2021-09-02 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| US20180271853A1 (en) * | 2015-01-09 | 2018-09-27 | Metastat, Inc. | Method of Use for Inhibitors of Epidermal Growth Factor Receptor Variant III |
| US11459390B2 (en) | 2015-01-16 | 2022-10-04 | Novartis Ag | Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor |
| US20180170992A1 (en) | 2015-01-26 | 2018-06-21 | The University Of Chicago | CAR T CELLS RECOGNIZING CANCER-SPECIFIC IL 13Ra2 |
| EP3250609A4 (en) | 2015-01-26 | 2018-07-11 | The University of Chicago | Il13ra alpha 2 binding agents and use thereof in cancer treatment |
| WO2016126608A1 (en) * | 2015-02-02 | 2016-08-11 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| US20160228547A1 (en) * | 2015-02-06 | 2016-08-11 | Batu Biologics, Inc. | Chimeric antigen receptor targeting of tumor endothelium |
| CN107427510A (zh) * | 2015-02-12 | 2017-12-01 | 万春药业公司 | 普那布林联合免疫检查点抑制剂的用途 |
| MX2017011374A (es) | 2015-03-06 | 2018-01-23 | Beyondspring Pharmaceuticals Inc | Método de tratamiento de cáncer asociado con una mutación de ras. |
| BR112017021500A2 (pt) | 2015-04-08 | 2018-09-25 | Novartis Ag | terapias com cd20, terapias com cd22 e terapias de combinação com uma célula que expressa (car) receptor de antígeno quimérico de cd19 |
| WO2016168809A1 (en) * | 2015-04-17 | 2016-10-20 | Krishnan Nandabalan | Compositions and methods for preventing tumor growth and treating cancer by targeting lectin galactoside-binding soluble 3 binding protein |
| CA2982996A1 (en) | 2015-04-17 | 2016-10-20 | David Maxwell Barrett | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
| GB201507368D0 (en) * | 2015-04-30 | 2015-06-17 | Ucl Business Plc | Cell |
| US20180117053A1 (en) * | 2015-05-27 | 2018-05-03 | Metastat, Inc. | The Method of Use for Inhibitors of Epidermal Growth Factor Receptor Variants II, III and VI |
| CA2986604A1 (en) * | 2015-06-26 | 2016-12-29 | University Of Southern California | Masking chimeric antigen receptor t cells for tumor-specific activation |
| EP3334726B1 (en) | 2015-07-13 | 2022-03-16 | Beyondspring Pharmaceuticals, Inc. | Plinabulin compositions |
| US10829735B2 (en) | 2015-07-21 | 2020-11-10 | The Trustees Of The University Of Pennsylvania | Methods for improving the efficacy and expansion of immune cells |
| US11667691B2 (en) | 2015-08-07 | 2023-06-06 | Novartis Ag | Treatment of cancer using chimeric CD3 receptor proteins |
| JP6905163B2 (ja) | 2015-09-03 | 2021-07-21 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | サイトカイン放出症候群を予測するバイオマーカー |
| MA44909A (fr) | 2015-09-15 | 2018-07-25 | Acerta Pharma Bv | Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk |
| CN105331585A (zh) * | 2015-11-13 | 2016-02-17 | 科济生物医药（上海）有限公司 | 携带pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞 |
| SG11201804373VA (en) | 2015-12-04 | 2018-06-28 | Novartis Ag | Compositions and methods for immunooncology |
| EP3393504A1 (en) | 2015-12-22 | 2018-10-31 | Novartis AG | Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy |
| JP2019500394A (ja) | 2015-12-30 | 2019-01-10 | ノバルティス アーゲー | 有効性が増強された免疫エフェクター細胞治療 |
| CN106967681B (zh) * | 2016-01-13 | 2020-06-05 | 北京马力喏生物科技有限公司 | 治疗脑胶质母细胞瘤的治疗组合物 |
| CN106967685B (zh) * | 2016-01-13 | 2020-06-02 | 北京马力喏生物科技有限公司 | 共表达抗EGFRvIII嵌合抗原受体和免疫检查点抑制分子的转基因淋巴细胞及其用途 |
| CN106967684A (zh) * | 2016-01-13 | 2017-07-21 | 北京马力喏生物科技有限公司 | 共表达抗EGFRvIII嵌合抗原受体和无功能EGFR受体的转基因淋巴细胞及其用途 |
| CN109219618B (zh) | 2016-01-21 | 2022-08-09 | 辉瑞大药厂 | 针对表皮生长因子受体变体iii和cd3的单特异性和双特异性抗体及其用途 |
| TWI755547B (zh) * | 2016-01-21 | 2022-02-21 | 美商輝瑞股份有限公司 | 靶向表皮生長因子受體變異體iii之嵌合型抗原受體 |
| US20230000912A1 (en) * | 2016-01-25 | 2023-01-05 | The Broad Institute, Inc. | Genetic, developmental and micro-environmental programs in idh-mutant gliomas, compositions of matter and methods of use thereof |
| CN107034193B (zh) * | 2016-02-03 | 2020-06-05 | 北京马力喏生物科技有限公司 | 治疗b细胞白血病及b细胞淋巴瘤的治疗组合物 |
| WO2017133175A1 (en) * | 2016-02-04 | 2017-08-10 | Nanjing Legend Biotech Co., Ltd. | Engineered mammalian cells for cancer therapy |
| RU2753543C1 (ru) | 2016-02-08 | 2021-08-17 | Бейондспринг Фармасьютикалс, Инк. | Композиции, содержащие тукаресол или его аналоги |
| US20200281973A1 (en) | 2016-03-04 | 2020-09-10 | Novartis Ag | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore |
| US11111505B2 (en) | 2016-03-19 | 2021-09-07 | Exuma Biotech, Corp. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
| US11325948B2 (en) | 2016-03-19 | 2022-05-10 | Exuma Biotech Corp. | Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL |
| US11549099B2 (en) | 2016-03-23 | 2023-01-10 | Novartis Ag | Cell secreted minibodies and uses thereof |
| US10654934B2 (en) | 2016-04-01 | 2020-05-19 | Innovative Cellular Therapeutics CO., LTD. | Use of chimeric antigen receptor modified cells to treat cancer |
| CN113082201B (zh) * | 2016-04-01 | 2024-07-05 | 上海斯丹赛生物技术有限公司 | 刺激t细胞介导的对表达抗原的细胞群的免疫应答的方法 |
| WO2017176289A1 (en) * | 2016-04-08 | 2017-10-12 | Celgene Corporation | Uses of lenalidomide and car t-cells |
| ES2944607T3 (es) | 2016-04-15 | 2023-06-22 | Novartis Ag | Composiciones y métodos para la expresión selectiva de receptores quiméricos para el antígeno |
| IL262404B2 (en) | 2016-05-13 | 2024-04-01 | Bioatla Llc | Antibodies, Antibody Fragments and Their Immunomodules Against ROR2 and Their Uses |
| CN118304304A (zh) | 2016-06-06 | 2024-07-09 | 大连万春布林医药有限公司 | 用于减少中性粒细胞减少症的组合物和方法 |
| WO2017214462A2 (en) | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-cd98 antibodies and antibody drug conjugates |
| MX2018015277A (es) | 2016-06-08 | 2019-09-06 | Abbvie Inc | Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco. |
| EP3468599A2 (en) | 2016-06-08 | 2019-04-17 | AbbVie Inc. | Anti-cd98 antibodies and antibody drug conjugates |
| IL300274A (en) | 2016-06-08 | 2023-04-01 | Abbvie Inc | Antibodies against B7–H3 and conjugates of drug and antibody |
| MX2018015274A (es) | 2016-06-08 | 2019-10-07 | Abbvie Inc | Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco. |
| BR112018075649A2 (pt) | 2016-06-08 | 2019-04-09 | Abbvie Inc. | anticorpos anti-b7-h3 e conjugados de fármaco de anticorpo |
| CN107556386A (zh) * | 2016-06-30 | 2018-01-09 | 中国科学院深圳先进技术研究院 | 抗EGFRvIII和CD3特异性双靶向抗体、含双靶向抗体表达盒的微环DNA及应用 |
| AU2017292936C1 (en) * | 2016-07-08 | 2024-05-02 | Exuma Biotech, Corp. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
| EP4302834A3 (en) | 2016-07-12 | 2024-07-17 | Revolution Medicines, Inc. | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors |
| CA3030837A1 (en) | 2016-07-15 | 2018-01-18 | Novartis Ag | Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor |
| AU2017302668B9 (en) | 2016-07-28 | 2023-06-22 | Novartis Ag | Combination therapies of chimeric antigen receptors and PD-1 inhibitors |
| JOP20170154B1 (ar) * | 2016-08-01 | 2023-03-28 | Omeros Corp | تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة |
| JP2019527696A (ja) * | 2016-08-01 | 2019-10-03 | ノバルティス アーゲー | プロｍ２マクロファージ分子の阻害剤と組み合わせてキメラ抗原受容体を用いる癌の処置 |
| CN109789164B (zh) * | 2016-08-30 | 2023-04-28 | 亘喜生物科技（上海）有限公司 | 具有gitr胞内结构域作为共刺激结构域的嵌合抗原受体 |
| EP3519577A1 (en) | 2016-09-28 | 2019-08-07 | Novartis AG | Porous membrane-based macromolecule delivery system |
| EP3523331A1 (en) | 2016-10-07 | 2019-08-14 | Novartis AG | Chimeric antigen receptors for the treatment of cancer |
| CN108203718A (zh) * | 2016-12-20 | 2018-06-26 | 上海生博生物医药科技有限公司 | 靶向EGFRvIII干扰PD-1降低肿瘤免疫逃逸的CAR-T载体及构建方法和应用 |
| EP3567049A4 (en) * | 2016-12-28 | 2020-08-26 | Green Cross Lab Cell Corporation | CHIMERA ANTIGEN RECEPTOR AND NATURAL KILLER CELLS FOR EXPRESSION FROM IT |
| JP2020503363A (ja) | 2017-01-06 | 2020-01-30 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | チューブリン結合化合物およびその治療的使用 |
| US20190328787A1 (en) * | 2017-01-10 | 2019-10-31 | The General Hospital Corporation | T cells expressing a chimeric antigen receptor |
| MX2019008696A (es) | 2017-01-23 | 2019-09-13 | Revolution Medicines Inc | Compuestos de piridina como inhibidores de shp2 alostericos. |
| TWI820013B (zh) | 2017-01-23 | 2023-11-01 | 美商銳新醫藥公司 | 作為別構ｓｈｐ２抑制劑之雙環化合物 |
| CN106636003B (zh) * | 2017-01-24 | 2019-07-12 | 深圳普瑞金生物药业有限公司 | 一种全人源化EGFRvIII嵌合抗原受体T细胞及其制备方法 |
| US11535662B2 (en) | 2017-01-26 | 2022-12-27 | Novartis Ag | CD28 compositions and methods for chimeric antigen receptor therapy |
| CN110582509A (zh) | 2017-01-31 | 2019-12-17 | 诺华股份有限公司 | 使用具有多特异性的嵌合t细胞受体蛋白治疗癌症 |
| KR20240110997A (ko) | 2017-02-01 | 2024-07-16 | 비욘드스프링 파마수티컬스, 인코포레이티드. | 호중구감소증의 감소 방법 |
| CN110612119A (zh) | 2017-02-07 | 2019-12-24 | 西雅图儿童医院（Dba西雅图儿童研究所） | 磷脂醚(ple)car t细胞肿瘤靶向(ctct)剂 |
| WO2018160622A1 (en) | 2017-02-28 | 2018-09-07 | Endocyte, Inc. | Compositions and methods for car t cell therapy |
| RU2019133280A (ru) | 2017-03-22 | 2021-04-22 | Новартис Аг | Композиции и способы для иммуноонкологии |
| AU2018243571B2 (en) | 2017-03-31 | 2024-03-07 | The Board Of Trustees Of The Leland Standford Junior University | Methods of treating T cell exhaustion by inhibiting or modulating T cell receptor signaling |
| US20200113940A1 (en) * | 2017-04-14 | 2020-04-16 | The General Hospital Corporation | Chimeric antigen receptor t cells targeting the tumor microenvironment |
| AU2018256436A1 (en) | 2017-04-19 | 2019-11-07 | Board Of Regents, The University Of Texas System | Immune cells expressing engineered antigen receptors |
| US11413310B2 (en) | 2017-06-02 | 2022-08-16 | Juno Therapeutics, Inc. | Articles of manufacture and methods for treatment using adoptive cell therapy |
| AU2018306307A1 (en) * | 2017-07-25 | 2020-02-20 | Board Of Regents, The University Of Texas System | Enhanced chimeric antigen receptors and use thereof |
| JP2020530993A (ja) * | 2017-08-02 | 2020-11-05 | オートラス リミテッド | キメラ抗原受容体または改変ｔｃｒを発現し、選択的に発現されるヌクレオチド配列を含む細胞 |
| AU2018313950A1 (en) | 2017-08-09 | 2020-02-13 | Juno Therapeutics, Inc. | Methods for producing genetically engineered cell compositions and related compositions |
| KR20200051684A (ko) | 2017-09-07 | 2020-05-13 | 레볼루션 메디슨즈, 인크. | 암 치료를 위한 shp2 억제제 조성물 및 방법 |
| MX2020002901A (es) | 2017-09-19 | 2020-07-22 | Massachusetts Inst Technology | Composiciones para la terapia con celulas t con receptores de antigeno quimerico y usos de las mismas. |
| MX2020003579A (es) | 2017-10-12 | 2020-07-22 | Revolution Medicines Inc | Compuestos de piridina, pirazina, y triazina como inhibidores de shp2 alostericos. |
| CA3077171A1 (en) * | 2017-10-17 | 2019-04-25 | The General Hospital Corporation | Methods and compositions relating to engineered regulatory t cells |
| JP2021501570A (ja) | 2017-10-18 | 2021-01-21 | ノバルティス アーゲー | 選択的タンパク質分解のための組成物及び方法 |
| RU2020116579A (ru) | 2017-10-25 | 2021-11-25 | Новартис Аг | Способы получения клеток, экспрессирующих химерный антигенный рецептор |
| CN109706120A (zh) * | 2017-10-26 | 2019-05-03 | 深圳宾德生物技术有限公司 | 一种双靶点特异性t淋巴细胞及其制备方法和应用 |
| CN111683962A (zh) | 2017-11-10 | 2020-09-18 | 美国政府(由卫生和人类服务部的部长所代表) | 靶向肿瘤抗原的嵌合抗原受体 |
| US11649294B2 (en) | 2017-11-14 | 2023-05-16 | GC Cell Corporation | Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
| JP2021503885A (ja) | 2017-11-22 | 2021-02-15 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 末梢血からの末梢血リンパ球（ｐｂｌ）の拡大培養 |
| WO2019104037A1 (en) * | 2017-11-22 | 2019-05-31 | The Brigham And Women's Hospital, Inc. | Msc-expressed immunomodulators in combination with car-t for cancer therapy |
| CN109836493A (zh) * | 2017-11-25 | 2019-06-04 | 深圳宾德生物技术有限公司 | 一种靶向cd19的单链抗体、嵌合抗原受体t细胞及其制备方法和应用 |
| CN109837292A (zh) * | 2017-11-25 | 2019-06-04 | 深圳宾德生物技术有限公司 | 一种敲除pd1的靶向egfr的嵌合抗原受体t细胞及其制备方法和应用 |
| CN109836497A (zh) * | 2017-11-25 | 2019-06-04 | 深圳宾德生物技术有限公司 | 一种靶向egfr的单链抗体、嵌合抗原受体t细胞及其制备方法和应用 |
| WO2019114762A1 (zh) * | 2017-12-12 | 2019-06-20 | 科济生物医药（上海）有限公司 | 免疫效应细胞和辐射联用治疗肿瘤 |
| CN109912715A (zh) * | 2017-12-13 | 2019-06-21 | 凯惠科技发展(上海)有限公司 | 一种EGFRvIII抗体及其偶联物、制备方法和应用 |
| MX2020006273A (es) | 2017-12-15 | 2020-09-14 | Revolution Medicines Inc | Compuestos policiclicos como inhibidores alostericos de shp2. |
| JP2021508246A (ja) * | 2017-12-21 | 2021-03-04 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 新規抗原結合部分の特異性試験のためのｃａｒ−ｔ細胞アッセイ |
| RU2707535C2 (ru) * | 2017-12-28 | 2019-11-27 | Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) | Генетическая конструкция, кодирующая структуру т-клеточного химерного рецептора на основе одноцепочечных vhh-антител, специфичных опухолевому рецептору cd47, для нацеленной иммунотерапии злокачественных новообразований |
| CN108103105A (zh) * | 2017-12-29 | 2018-06-01 | 深圳市茵冠生物科技有限公司 | 一种car-t细胞的制备方法、制得的car-t细胞及其应用 |
| CN112218651A (zh) * | 2018-01-08 | 2021-01-12 | 诺华公司 | 用于与嵌合抗原受体疗法组合的免疫增强rna |
| CN111801421A (zh) | 2018-01-12 | 2020-10-20 | 酷罗赛尔公司 | 使用双重shrna的增强的免疫细胞及包含免疫细胞的组合物 |
| US11311576B2 (en) | 2018-01-22 | 2022-04-26 | Seattle Children's Hospital | Methods of use for CAR T cells |
| CN108276495B (zh) * | 2018-01-24 | 2022-03-18 | 博生吉医药科技(苏州)有限公司 | 靶向csf1r嵌合抗原受体修饰的nk92mi细胞和t细胞及其制法和应用 |
| CA3089226A1 (en) | 2018-01-24 | 2019-08-01 | Beyondspring Pharmaceuticals, Inc. | Composition and method for reducing thrombocytopenia via the administration of plinabulin |
| EP3746116A1 (en) | 2018-01-31 | 2020-12-09 | Novartis AG | Combination therapy using a chimeric antigen receptor |
| EP3752170A4 (en) * | 2018-02-12 | 2022-03-30 | The General Hospital Corporation | CHIMERA ANTIGEN RECEPTOR T-CELLS TARGETED AGAINST THE TUMOR MICRO ENVIRONMENT |
| CN110157674A (zh) * | 2018-02-12 | 2019-08-23 | 深圳宾德生物技术有限公司 | 一种靶向性t淋巴细胞及其制备方法和应用 |
| CN110144328A (zh) * | 2018-02-12 | 2019-08-20 | 深圳宾德生物技术有限公司 | 一种靶向性抗肿瘤t细胞及其制备方法和应用 |
| WO2019160956A1 (en) | 2018-02-13 | 2019-08-22 | Novartis Ag | Chimeric antigen receptor therapy in combination with il-15r and il15 |
| JP2021514662A (ja) * | 2018-03-08 | 2021-06-17 | フェインズ セラピューティクス，インコーポレーテッド | 抗ｔｉｐ−１抗体及びその使用 |
| US12090170B2 (en) | 2018-04-06 | 2024-09-17 | The Regents Of The University Of California | Methods of treating glioblastomas |
| CA3096202A1 (en) * | 2018-04-06 | 2019-10-10 | The Regents Of The University Of California | Methods of treating egfrviii expressing glioblastomas |
| WO2019210153A1 (en) | 2018-04-27 | 2019-10-31 | Novartis Ag | Car t cell therapies with enhanced efficacy |
| US20210396739A1 (en) | 2018-05-01 | 2021-12-23 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
| EP3801769A1 (en) | 2018-05-25 | 2021-04-14 | Novartis AG | Combination therapy with chimeric antigen receptor (car) therapies |
| AU2019278886A1 (en) * | 2018-06-01 | 2020-12-24 | Beyondspring Pharmaceuticals, Inc. | Composition and method of treating cancer associated with EGFR mutation |
| US20210123075A1 (en) | 2018-06-08 | 2021-04-29 | Novartis Ag | Compositions and methods for immunooncology |
| CN112203725A (zh) | 2018-06-13 | 2021-01-08 | 诺华股份有限公司 | Bcma嵌合抗原受体及其用途 |
| CN108707198A (zh) * | 2018-06-28 | 2018-10-26 | 李永海 | 识别人c-Met蛋白的人源单链抗体、诊断试剂及其CAR-T细胞制剂 |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| CN110714018B (zh) * | 2018-07-11 | 2023-10-03 | 上海恒润达生生物科技股份有限公司 | 靶向egfrviii的嵌合抗原受体及其用途 |
| CN112739340A (zh) | 2018-07-23 | 2021-04-30 | 美真达治疗公司 | 抗cd5抗体药物缀合物(adc)在同种异体细胞疗法中的用途 |
| CN113366017B (zh) | 2018-08-10 | 2024-05-28 | 优特力克斯有限公司 | 结合hla-dr的嵌合抗原受体和car-t细胞 |
| US20210171909A1 (en) | 2018-08-31 | 2021-06-10 | Novartis Ag | Methods of making chimeric antigen receptor?expressing cells |
| CN112639083A (zh) | 2018-08-31 | 2021-04-09 | 诺华股份有限公司 | 制备表达嵌合抗原受体的细胞的方法 |
| CN109265563B (zh) * | 2018-09-26 | 2020-01-31 | 武汉波睿达生物科技有限公司 | 一种用于治疗血液肿瘤的人源嵌合抗原受体及其应用 |
| AU2019346335B2 (en) | 2018-09-28 | 2024-07-25 | Massachusetts Institute Of Technology | Collagen-localized immunomodulatory molecules and methods thereof |
| WO2020092455A2 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Car t cell transcriptional atlas |
| CN109485731A (zh) * | 2018-11-02 | 2019-03-19 | 广东克瑞斯普生物科技有限公司 | 一种靶向EGFRvIII的嵌合抗原受体 |
| CN109536455B (zh) * | 2018-12-11 | 2020-02-21 | 武汉波睿达生物科技有限公司 | 一种car-nk细胞及其制备方法和应用 |
| US20240245670A1 (en) | 2018-12-20 | 2024-07-25 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| JP2022519577A (ja) * | 2019-02-01 | 2022-03-24 | ウニベルシテート バーゼル | 養子細胞移植療法における使用のためのカルシニューリン阻害剤耐性免疫細胞 |
| EP3924054A1 (en) | 2019-02-15 | 2021-12-22 | Novartis AG | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| JP7488826B2 (ja) | 2019-02-15 | 2024-05-22 | ノバルティス アーゲー | 置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用 |
| EP3927371A1 (en) | 2019-02-22 | 2021-12-29 | Novartis AG | Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors |
| JP2022523204A (ja) | 2019-02-25 | 2022-04-21 | ノバルティス アーゲー | ウイルス送達のためのメソポーラスシリカ粒子組成物 |
| MX2021010288A (es) | 2019-03-01 | 2021-09-23 | Iovance Biotherapeutics Inc | Expansion de linfocitos infiltrantes de tumores a partir de tumores liquidos y usos terapeuticos de los mismos. |
| WO2020191316A1 (en) | 2019-03-21 | 2020-09-24 | Novartis Ag | Car-t cell therapies with enhanced efficacy |
| US20220168389A1 (en) | 2019-04-12 | 2022-06-02 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| EP3959320A1 (en) | 2019-04-24 | 2022-03-02 | Novartis AG | Compositions and methods for selective protein degradation |
| EP3990491A1 (en) | 2019-06-26 | 2022-05-04 | Massachusetts Institute of Technology | Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof |
| CN112430577A (zh) * | 2019-08-26 | 2021-03-02 | 深圳宾德生物技术有限公司 | 靶向EGFRvⅢ并干扰IL-6表达的嵌合抗原受体T细胞及其制备方法和应用 |
| WO2021061648A1 (en) | 2019-09-23 | 2021-04-01 | Massachusetts Institute Of Technology | Methods and compositions for stimulation of endogenous t cell responses |
| WO2021087356A1 (en) * | 2019-11-01 | 2021-05-06 | The Trustees Of The University Of Pennsylvania | Fibronectin targeting chimeric antigen receptors (cars) |
| AU2020394441A1 (en) | 2019-11-26 | 2022-06-02 | Novartis Ag | CD19 and CD22 chimeric antigen receptors and uses thereof |
| IL293215A (en) | 2019-11-26 | 2022-07-01 | Novartis Ag | Chimeric antigen receptors that bind bcma and cd19 and their uses |
| WO2021123902A1 (en) | 2019-12-20 | 2021-06-24 | Novartis Ag | Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome |
| EP4110376A2 (en) | 2020-02-27 | 2023-01-04 | Novartis AG | Methods of making chimeric antigen receptor-expressing cells |
| MX2022010685A (es) | 2020-02-27 | 2022-09-23 | Novartis Ag | Metodos de produccion de celulas que expresan receptores de antigeno quimericos. |
| MX2022011080A (es) | 2020-03-10 | 2023-01-04 | Massachusetts Inst Technology | Metodos para generar celulas nk de tipo memoria modificadas y composiciones de las mismas. |
| JP2023517889A (ja) | 2020-03-10 | 2023-04-27 | マサチューセッツ インスティテュート オブ テクノロジー | ＮＰＭ１ｃ陽性がんの免疫療法のための組成物および方法 |
| WO2021221782A1 (en) | 2020-05-01 | 2021-11-04 | Massachusetts Institute Of Technology | Chimeric antigen receptor-targeting ligands and uses thereof |
| US20210340524A1 (en) | 2020-05-01 | 2021-11-04 | Massachusetts Institute Of Technology | Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof |
| WO2021252920A1 (en) | 2020-06-11 | 2021-12-16 | Novartis Ag | Zbtb32 inhibitors and uses thereof |
| KR20230027056A (ko) | 2020-06-23 | 2023-02-27 | 노파르티스 아게 | 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 |
| KR20230152783A (ko) | 2020-07-07 | 2023-11-03 | 칸큐어 엘엘씨 | Mic 항체 및 결합제 및 이의 사용 방법 |
| US20230271940A1 (en) | 2020-08-03 | 2023-08-31 | Novartis Ag | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| EP4199960A2 (en) | 2020-08-21 | 2023-06-28 | Novartis AG | Compositions and methods for in vivo generation of car expressing cells |
| CN112661844B (zh) * | 2020-11-18 | 2022-05-03 | 贵州医科大学 | 一种靶向EGFRvIII的单链抗体及应用 |
| JP2023550148A (ja) | 2020-11-20 | 2023-11-30 | シンシア・イノベーション・インコーポレイテッド | がん免疫治療に用いられる武装二重ｃａｒ－ｔ組成物及び方法 |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| CN112480266B (zh) * | 2020-12-04 | 2021-07-06 | 广州熙帝生物科技有限公司 | 一种嵌合抗原受体、嵌合抗原受体脐血有核细胞及应用 |
| CN116635064A (zh) | 2020-12-18 | 2023-08-22 | 世纪治疗股份有限公司 | 具有适应性受体特异性的嵌合抗原受体系统 |
| UY39610A (es) | 2021-01-20 | 2022-08-31 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| AU2022267410A1 (en) * | 2021-04-26 | 2023-11-09 | Myrio Therapeutics Pty Ltd | EGFRvIII BINDING PROTEINS |
| WO2022229853A1 (en) | 2021-04-27 | 2022-11-03 | Novartis Ag | Viral vector production system |
| CN113402616B (zh) * | 2021-06-18 | 2022-09-23 | 浙江大学 | 巨噬细胞专属嵌合抗原受体、表达该受体的可控极化单核/巨噬细胞及其制备方法和应用 |
| AU2022312311A1 (en) * | 2021-07-16 | 2024-02-08 | Noile-Immune Biotech Inc. | Anti-EGFRviii antibody, polypeptide, cell capable of expressing said polypeptide, pharmaceutical composition comprising said cell, method for producing said cell, and polynucleotide or vector comprising nucleotide sequence encoding said polypeptide |
| WO2023010065A2 (en) * | 2021-07-29 | 2023-02-02 | Cephalon Llc | Compositions and methods for anti-pacap antibodies |
| CN113980138B (zh) * | 2021-08-11 | 2023-08-11 | 卡瑞济(北京)生命科技有限公司 | EphA2嵌合抗原受体以及其用途 |
| CA3229746A1 (en) | 2021-08-20 | 2023-02-23 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| WO2023081715A1 (en) | 2021-11-03 | 2023-05-11 | Viracta Therapeutics, Inc. | Combination of car t-cell therapy with btk inhibitors and methods of use thereof |
| CN114106201A (zh) * | 2021-11-25 | 2022-03-01 | 广西医科大学 | 一种基于纳米抗体靶向EGFRvIII的嵌合抗原受体T细胞的制备方法及其应用 |
| AR128124A1 (es) | 2021-12-30 | 2024-03-27 | Tr1X Inc | Células t cd4⁺ que expresan il-10 y receptores de antígenos quiméricos y usos de estos |
| WO2023214325A1 (en) | 2022-05-05 | 2023-11-09 | Novartis Ag | Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors |
| WO2024027835A1 (zh) * | 2022-08-05 | 2024-02-08 | 北京鼎成肽源生物技术有限公司 | 靶向EGFRvIII的抗体及其在细胞免疫治疗的应用 |
| WO2024089639A1 (en) | 2022-10-26 | 2024-05-02 | Novartis Ag | Lentiviral formulations |
| WO2024098024A1 (en) | 2022-11-04 | 2024-05-10 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof |
Family Cites Families (245)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| CA1322714C (en) | 1986-11-14 | 1993-10-05 | Harry N. Antoniades | Wound healing and bone regeneration |
| US5906936A (en) | 1988-05-04 | 1999-05-25 | Yeda Research And Development Co. Ltd. | Endowing lymphocytes with antibody specificity |
| US6303121B1 (en) | 1992-07-30 | 2001-10-16 | Advanced Research And Technology | Method of using human receptor protein 4-1BB |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| DE69025946T2 (de) | 1989-09-08 | 1996-10-17 | Univ Duke | Modifikationen der struktur des egf-rezeptor-gens in menschlichen glioma |
| US5981725A (en) | 1989-09-08 | 1999-11-09 | The Johns Hopkins Univiersity | Structural alterations of the EGF receptor gene in human tumors |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US6319494B1 (en) | 1990-12-14 | 2001-11-20 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
| DK0517895T3 (da) | 1990-12-14 | 1997-04-07 | Univ California | Kimæriske kæder til receptorforbundne signaltransduktionsveje |
| US6004811A (en) | 1991-03-07 | 1999-12-21 | The Massachussetts General Hospital | Redirection of cellular immunity by protein tyrosine kinase chimeras |
| IL101147A (en) | 1991-03-07 | 2004-06-20 | Gen Hospital Corp | Change of direction of cellular immunity by chimera receptors |
| US7049136B2 (en) | 1991-03-07 | 2006-05-23 | The General Hospital Corporation | Redirection of cellular immunity by receptor chimeras |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| US5199942A (en) | 1991-06-07 | 1993-04-06 | Immunex Corporation | Method for improving autologous transplantation |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| CA2103887C (en) | 1991-12-13 | 2005-08-30 | Gary M. Studnicka | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| GB9300059D0 (en) | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| US8211422B2 (en) | 1992-03-18 | 2012-07-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric receptor genes and cells transformed therewith |
| IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
| TW225528B (ja) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
| US5350674A (en) | 1992-09-04 | 1994-09-27 | Becton, Dickinson And Company | Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US7211259B1 (en) | 1993-05-07 | 2007-05-01 | Immunex Corporation | 4-1BB polypeptides and DNA encoding 4-1BB polypeptides |
| EP0758394B1 (en) | 1994-05-02 | 2002-11-20 | Bernd Groner | Bifunctional protein, preparation and use |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
| US5712149A (en) | 1995-02-03 | 1998-01-27 | Cell Genesys, Inc. | Chimeric receptor molecules for delivery of co-stimulatory signals |
| US6103521A (en) | 1995-02-06 | 2000-08-15 | Cell Genesys, Inc. | Multispecific chimeric receptors |
| NZ302513A (en) | 1995-02-24 | 1999-11-29 | Gen Hospital Corp | Chimeric receptors for redirecting cellular immunity |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| DE69619114T2 (de) | 1995-07-06 | 2002-10-02 | Novartis Ag, Basel | Pyrolopyrimidine und verfahren zu ihrer herstellung |
| GB9526131D0 (en) | 1995-12-21 | 1996-02-21 | Celltech Therapeutics Ltd | Recombinant chimeric receptors |
| US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| US5874240A (en) | 1996-03-15 | 1999-02-23 | Human Genome Sciences, Inc. | Human 4-1BB receptor splicing variant |
| DK0892789T4 (da) | 1996-04-12 | 2010-04-06 | Warner Lambert Co | Irreversible inhibitorer af tyrosin kinaser |
| ES2249800T3 (es) | 1996-06-24 | 2006-04-01 | Pfizer Inc. | Derivados triciclicos sustituidos con fenilamino para el tratamento de enfermedades hiperproliferativas. |
| CA2265630A1 (en) | 1996-09-13 | 1998-03-19 | Gerald Mcmahon | Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders |
| US6114148C1 (en) | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
| EP0837063A1 (en) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
| CA2269738A1 (en) | 1996-10-25 | 1998-05-07 | Mitchell H. Finer | Targeted cytolysis of cancer cells |
| US20030060444A1 (en) | 1997-06-25 | 2003-03-27 | Celltech Therapeutics, Ltd. | Cell activation process and reagents therefor |
| GB9713473D0 (en) | 1997-06-25 | 1997-09-03 | Celltech Therapeutics Ltd | Biological products |
| CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
| GB9809658D0 (en) | 1998-05-06 | 1998-07-01 | Celltech Therapeutics Ltd | Biological products |
| EP1109921A4 (en) | 1998-09-04 | 2002-08-28 | Sloan Kettering Inst Cancer | FOR PROSTATE-SPECIFIC MEMBRANE-ANTI-SPECIFIC FUSION RECEPTORS AND THEIR USE |
| AU2472400A (en) | 1998-10-20 | 2000-05-08 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
| US7052906B1 (en) | 1999-04-16 | 2006-05-30 | Celltech R & D Limited | Synthetic transmembrane components |
| CA2386270A1 (en) | 1999-10-15 | 2001-04-26 | University Of Massachusetts | Rna interference pathway genes as tools for targeted genetic interference |
| GB9925848D0 (en) | 1999-11-01 | 1999-12-29 | Celltech Therapeutics Ltd | Biological products |
| US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| MXPA02008265A (es) | 2000-02-24 | 2004-09-10 | Xcyte Therapies Inc | Concentracion y estimulacion simultanea de calulas. |
| UA77157C2 (en) | 2000-02-25 | 2006-11-15 | Polypeptide anti-egfrviii scfvs with improved cytotoxicity and output, molecule of nucleic acid, that codes the indicated polypeptide, and method of cell destructure with using of this polypeptide | |
| IL136511A0 (en) | 2000-06-01 | 2001-06-14 | Gavish Galilee Bio Appl Ltd | Genetically engineered mhc molecules |
| AU2001275474A1 (en) | 2000-06-12 | 2001-12-24 | Akkadix Corporation | Materials and methods for the control of nematodes |
| GB0025307D0 (en) | 2000-10-16 | 2000-11-29 | Celltech Chiroscience Ltd | Biological products |
| EP1334188B1 (en) | 2000-11-07 | 2006-08-30 | City of Hope | Cd19-specific redirected immune cells |
| US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
| CN1294148C (zh) | 2001-04-11 | 2007-01-10 | 中国科学院遗传与发育生物学研究所 | 环状单链三特异抗体 |
| WO2002088334A1 (en) | 2001-04-30 | 2002-11-07 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| US7514537B2 (en) | 2001-04-30 | 2009-04-07 | City Of Hope | Chimeric immunoreceptor useful in treating human gliomas |
| US20030148982A1 (en) | 2001-11-13 | 2003-08-07 | Brenner Malcolm K. | Bi-spcific chimeric T cells |
| AU2003202908A1 (en) | 2002-01-03 | 2003-07-24 | The Trustees Of The University Of Pennsylvania | Activation and expansion of t-cells using an engineered multivalent signaling platform |
| US7745140B2 (en) | 2002-01-03 | 2010-06-29 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool |
| US7638326B2 (en) | 2002-01-03 | 2009-12-29 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an engineered multivalent signaling platform |
| EA008379B1 (ru) | 2002-02-01 | 2007-04-27 | Ариад Джин Терапьютикс, Инк. | Фосфорсодержащие соединения и их применения |
| CN100457181C (zh) * | 2002-03-04 | 2009-02-04 | 伊姆克罗尼系统公司 | 用血管内皮生长因子受体拮抗剂抑制肿瘤生长的联合疗法 |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| JP4511943B2 (ja) | 2002-12-23 | 2010-07-28 | ワイス エルエルシー | Ｐｄ−１に対する抗体およびその使用 |
| US20050129671A1 (en) | 2003-03-11 | 2005-06-16 | City Of Hope | Mammalian antigen-presenting T cells and bi-specific T cells |
| MXPA05014152A (es) | 2003-06-27 | 2006-05-25 | Abgenix Inc | Anticuerpos dirigidos a los mutantes de delecion de receptor de factor de crecimiento epidermico y sus usos. |
| EP1638510B1 (en) | 2003-07-01 | 2015-09-02 | Immunomedics, Inc. | Multivalent carriers of bi-specific antibodies |
| WO2005042743A2 (en) | 2003-08-18 | 2005-05-12 | Medimmune, Inc. | Humanization of antibodies |
| AU2004280333A1 (en) | 2003-08-22 | 2005-04-21 | Medimmune, Llc | Humanization of antibodies |
| WO2005019429A2 (en) | 2003-08-22 | 2005-03-03 | Potentia Pharmaceuticals, Inc. | Compositions and methods for enhancing phagocytosis or phagocyte activity |
| US20050113564A1 (en) | 2003-11-05 | 2005-05-26 | St. Jude Children's Research Hospital | Chimeric receptors with 4-1BB stimulatory signaling domain |
| US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
| EP1765988B1 (en) | 2004-05-27 | 2017-09-20 | The Trustees of The University of Pennsylvania | Novel artificial antigen presenting cells and uses therefor |
| EP1786918A4 (en) | 2004-07-17 | 2009-02-11 | Imclone Systems Inc | NEW BISPECIFIC ANTIBODY TETRAVALENT |
| US7994298B2 (en) | 2004-09-24 | 2011-08-09 | Trustees Of Dartmouth College | Chimeric NK receptor and methods for treating cancer |
| ES2766123T3 (es) | 2004-12-10 | 2020-06-11 | Peter Maccallum Cancer Inst | Métodos y composiciones para inmunoterapia adoptiva |
| KR101339628B1 (ko) | 2005-05-09 | 2013-12-09 | 메다렉스, 인코포레이티드 | 예정 사멸 인자 1(ｐｄ-1)에 대한 인간 모노클로날 항체, 및 항-ｐｄ-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법 |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| DK1907424T3 (en) | 2005-07-01 | 2015-11-09 | Squibb & Sons Llc | HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED death ligand 1 (PD-L1) |
| US20070036773A1 (en) | 2005-08-09 | 2007-02-15 | City Of Hope | Generation and application of universal T cells for B-ALL |
| SG2014010029A (en) | 2005-08-19 | 2014-08-28 | Abbott Lab | Dual variable domain immunoglobin and uses thereof |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| WO2008045437A2 (en) | 2006-10-09 | 2008-04-17 | The General Hospital Corporation | Chimeric t-cell receptors and t-cells targeting egfrviii on tumors |
| US20080131415A1 (en) | 2006-11-30 | 2008-06-05 | Riddell Stanley R | Adoptive transfer of cd8 + t cell clones derived from central memory cells |
| PT2856876T (pt) | 2007-03-30 | 2018-03-28 | Memorial Sloan Kettering Cancer Center | Expressão constitutiva de ligantes co-estimulatórios em linfócitos t adotivamente transferidos |
| BRPI0812913B8 (pt) | 2007-06-18 | 2021-05-25 | Merck Sharp & Dohme | anticorpos monoclonais ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotideo, método para produzir os referidos anticorpos ou fragmentos de anticorpos, composição que os compreende e uso dos mesmos |
| US8247397B2 (en) | 2007-09-12 | 2012-08-21 | Genentech, Inc. | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use |
| EP2214675B1 (en) | 2007-10-25 | 2013-11-20 | Genentech, Inc. | Process for making thienopyrimidine compounds |
| US10059923B2 (en) | 2008-01-30 | 2018-08-28 | Memorial Sloan Kettering Cancer Center | Methods for off-the-shelf tumor immunotherapy using allogeneic T-cell precursors |
| RU2531758C2 (ru) | 2008-02-11 | 2014-10-27 | Куретек Лтд. | Моноклональные антитела для лечения опухолей |
| US8379824B2 (en) | 2008-03-06 | 2013-02-19 | At&T Intellectual Property I, Lp | Methods and apparatus to provide a network-based caller identification service in a voice over internet protocol network |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| EA023148B1 (ru) | 2008-08-25 | 2016-04-29 | Эмплиммьюн, Инк. | Композиции на основе антагонистов pd-1 и их применение |
| CA2735006A1 (en) | 2008-08-25 | 2010-03-11 | Amplimmune, Inc. | Pd-1 antagonists and methods of use thereof |
| CA2735456C (en) | 2008-08-26 | 2021-11-16 | City Of Hope | Method and compositions for enhanced anti-tumor effector functioning of t cells |
| CN114835812A (zh) | 2008-12-09 | 2022-08-02 | 霍夫曼-拉罗奇有限公司 | 抗-pd-l1抗体及它们用于增强t细胞功能的用途 |
| US9206440B2 (en) | 2009-01-23 | 2015-12-08 | Roger Williams Hospital | Viral vectors encoding multiple highly homologus non-viral polypeptides and the use of same |
| JP5844159B2 (ja) | 2009-02-09 | 2016-01-13 | ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ | Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用 |
| WO2011041093A1 (en) | 2009-10-01 | 2011-04-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer |
| US9181527B2 (en) | 2009-10-29 | 2015-11-10 | The Trustees Of Dartmouth College | T cell receptor-deficient T cell compositions |
| JP2013512251A (ja) | 2009-11-24 | 2013-04-11 | アンプリミューン、インコーポレーテッド | Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害 |
| US9133436B2 (en) | 2010-02-04 | 2015-09-15 | The Trustees Of The University Of Pennsylvania | ICOS critically regulates the expansion and function of inflammatory human Th17 cells |
| SE535129C2 (sv) | 2010-07-13 | 2012-04-24 | Bostik Ab | Komposition för vidhäftning av ett golvmaterial |
| NZ728530A (en) | 2010-10-27 | 2017-06-30 | Baylor College Medicine | Chimeric cd27 receptors for redirecting t cells to cd70-positive malignancies |
| PT3214091T (pt) | 2010-12-09 | 2019-01-11 | Univ Pennsylvania | Utilização de células t modificadas por recetor de antigénio quimérico para tratar o cancro |
| CA3102782A1 (en) | 2010-12-14 | 2012-06-21 | University Of Maryland, Baltimore | Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer |
| KR20140004174A (ko) | 2011-01-18 | 2014-01-10 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 암 치료를 위한 조성물 및 방법 |
| WO2012127464A2 (en) | 2011-03-23 | 2012-09-27 | Gavish-Galilee Bio Applications Ltd | Constitutively activated t cells for use in adoptive cell therapy |
| US9987308B2 (en) | 2011-03-23 | 2018-06-05 | Fred Hutchinson Cancer Research Center | Method and compositions for cellular immunotherapy |
| ES2651510T3 (es) | 2011-04-01 | 2018-01-26 | Memorial Sloan-Kettering Cancer Center | Anticuerpos similares a receptores de células T específicos para un péptido de WT1 presentado por HLA-A2 |
| WO2012138858A1 (en) | 2011-04-08 | 2012-10-11 | Baylor College Of Medicine | Reversing the effects of the tumor microenvironment using chimeric cytokine receptors |
| AU2012240562B2 (en) | 2011-04-08 | 2016-12-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of same for the treatment of cancer |
| US20130071414A1 (en) | 2011-04-27 | 2013-03-21 | Gianpietro Dotti | Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies |
| CA3106285A1 (en) | 2011-07-25 | 2013-01-31 | Nationwide Children's Hospital, Inc. | Recombinant virus products and methods for inhibition of expression of dux4 |
| JP6334398B2 (ja) | 2011-07-29 | 2018-05-30 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | スイッチ共刺激受容体 |
| WO2013026837A1 (en) | 2011-08-23 | 2013-02-28 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
| DK2748201T3 (en) | 2011-08-23 | 2018-02-12 | Roche Glycart Ag | BISPECIFIC T-CELL ACTIVATING ANTIGIN BINDING MOLECULES |
| WO2013033626A2 (en) | 2011-08-31 | 2013-03-07 | Trustees Of Dartmouth College | Nkp30 receptor targeted therapeutics |
| WO2013040371A2 (en) | 2011-09-16 | 2013-03-21 | Baylor College Of Medicine | Targeting the tumor microenvironment using manipulated nkt cells |
| EA201490636A1 (ru) | 2011-09-16 | 2014-08-29 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Сконструированные с помощью рнк t-клетки для лечения злокачественных новообразований |
| WO2013059593A1 (en) | 2011-10-20 | 2013-04-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-cd22 chimeric antigen receptors |
| JP6074435B2 (ja) | 2011-10-26 | 2017-02-01 | ナショナル キャンサー センター | 変異ｃｔｌａ４遺伝子移入ｔ細胞及びこれを含む抗がん免疫治療用組成物 |
| US10391126B2 (en) | 2011-11-18 | 2019-08-27 | Board Of Regents, The University Of Texas System | CAR+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA |
| EP2814846B1 (en) | 2012-02-13 | 2020-01-08 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| KR20140127829A (ko) | 2012-02-22 | 2014-11-04 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 2세대 키메라 항원 수용체에서 cd2 시그널링 도메인의 용도 |
| IN2014DN07414A (ja) | 2012-02-22 | 2015-04-24 | Univ Pennsylvania | |
| JP2015513399A (ja) | 2012-02-22 | 2015-05-14 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 癌の治療のために有用なｔ細胞の存続的集団を作製するための組成物および方法 |
| WO2013126726A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Double transgenic t cells comprising a car and a tcr and their methods of use |
| CN103483452B (zh) | 2012-06-12 | 2021-08-13 | 上海细胞治疗集团有限公司 | 双信号独立的嵌合抗原受体及其用途 |
| BR112015000657B1 (pt) | 2012-07-13 | 2023-12-05 | The Trustees Of The University Of Pennsylvania | Uso de uma célula geneticamente modificada para expressar um car |
| KR20150029714A (ko) | 2012-07-13 | 2015-03-18 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 이중특이적 항체의 공-도입에 의한 ｃａｒ 세포의 활성 증강 |
| JP6382191B2 (ja) | 2012-07-13 | 2018-08-29 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | Ｃａｒの抗腫瘍活性のための毒性管理 |
| EP3584256A1 (en) | 2012-07-13 | 2019-12-25 | The Trustees Of The University Of Pennsylvania | Methods of assessing the suitability of transduced t cells for administration |
| WO2014011993A2 (en) | 2012-07-13 | 2014-01-16 | The Trustees Of The University Of Pennsylvania | Epitope spreading associated with car t-cells |
| AU2013289970A1 (en) | 2012-07-13 | 2015-01-22 | The Trustees Of The University Of Pennsylvania | Compositions and methods for regulating CAR T cells |
| PT2884999T (pt) | 2012-08-20 | 2021-01-05 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Método e composições para imunoterapêutica celular |
| US9937205B2 (en) | 2012-09-04 | 2018-04-10 | The Trustees Of The University Of Pennsylvania | Inhibition of diacylglycerol kinase to augment adoptive T cell transfer |
| US9365641B2 (en) | 2012-10-01 | 2016-06-14 | The Trustees Of The University Of Pennsylvania | Compositions and methods for targeting stromal cells for the treatment of cancer |
| WO2014055657A1 (en) | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
| AU2013204922B2 (en) | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
| ES2898270T3 (es) | 2013-02-06 | 2022-03-04 | Celgene Corp | Linfocitos T modificados con especificidad mejorada |
| WO2014130657A1 (en) | 2013-02-20 | 2014-08-28 | The Trustees Of The University Of Pennsylvania | Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor |
| US9573988B2 (en) | 2013-02-20 | 2017-02-21 | Novartis Ag | Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells |
| CN103113470B (zh) | 2013-02-27 | 2015-04-22 | 四川大学 | 靶向人egfr的基因工程化淋巴细胞及其制备方法和用途 |
| WO2014145252A2 (en) * | 2013-03-15 | 2014-09-18 | Milone Michael C | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| TWI654206B (zh) | 2013-03-16 | 2019-03-21 | 諾華公司 | 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症 |
| CN116478927A (zh) | 2013-12-19 | 2023-07-25 | 诺华股份有限公司 | 人间皮素嵌合抗原受体及其用途 |
| JP6793902B2 (ja) | 2013-12-20 | 2020-12-02 | ノバルティス アーゲー | 調節可能キメラ抗原受容体 |
| WO2015112626A1 (en) | 2014-01-21 | 2015-07-30 | June Carl H | Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules |
| ES2857226T3 (es) | 2014-03-15 | 2021-09-28 | Novartis Ag | Receptor de antígeno quimérico regulable |
| JP2017513818A (ja) | 2014-03-15 | 2017-06-01 | ノバルティス アーゲー | キメラ抗原受容体を使用する癌の処置 |
| IL293603B2 (en) | 2014-04-07 | 2024-03-01 | Novartis Ag | Cancer treatment using chimeric antigen receptor (CAR) against CD19 |
| MX2017001013A (es) | 2014-07-21 | 2018-02-21 | Novartis Ag | Tratamiento de cáncer usando un receptor quimérico de antígeno cll-1. |
| US20170274014A1 (en) | 2014-07-21 | 2017-09-28 | Jennifer Brogdon | Combinations of low, immune enhancing, doses of mtor inhibitors and cars |
| CN106687483B (zh) | 2014-07-21 | 2020-12-04 | 诺华股份有限公司 | 使用人源化抗-bcma嵌合抗原受体治疗癌症 |
| EP3194585A1 (en) | 2014-07-21 | 2017-07-26 | Novartis AG | Sortase molecules and uses thereof |
| WO2016014530A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Combinations of low, immune enhancing. doses of mtor inhibitors and cars |
| BR112017001242A2 (pt) | 2014-07-21 | 2017-12-05 | Novartis Ag | tratamento de câncer usando um receptor antigênico quimérico a cd33 |
| WO2016014553A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
| ES2781175T3 (es) | 2014-07-31 | 2020-08-31 | Novartis Ag | Subconjunto optimizado de células T que contienen un receptor de antígeno quimérico |
| CA2958200A1 (en) | 2014-08-14 | 2016-02-18 | Novartis Ag | Treatment of cancer using a gfr alpha-4 chimeric antigen receptor |
| CA2958553A1 (en) | 2014-08-19 | 2016-02-25 | Novartis Ag | Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment |
| US10577417B2 (en) | 2014-09-17 | 2020-03-03 | Novartis Ag | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| WO2016057705A1 (en) | 2014-10-08 | 2016-04-14 | Novartis Ag | Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof |
| US20170239294A1 (en) | 2014-10-15 | 2017-08-24 | Novartis Ag | Compositions and methods for treating b-lymphoid malignancies |
| AU2015374296B2 (en) | 2014-12-29 | 2021-09-02 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| US11459390B2 (en) | 2015-01-16 | 2022-10-04 | Novartis Ag | Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor |
| WO2016126608A1 (en) | 2015-02-02 | 2016-08-11 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| ES2876974T3 (es) | 2015-04-07 | 2021-11-15 | Novartis Ag | Combinación de terapia con receptor de antígeno quimérico y derivados de amino pirimidina |
| BR112017021500A2 (pt) | 2015-04-08 | 2018-09-25 | Novartis Ag | terapias com cd20, terapias com cd22 e terapias de combinação com uma célula que expressa (car) receptor de antígeno quimérico de cd19 |
| CA2982996A1 (en) | 2015-04-17 | 2016-10-20 | David Maxwell Barrett | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
| EP3286211A1 (en) | 2015-04-23 | 2018-02-28 | Novartis AG | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
| US10829735B2 (en) | 2015-07-21 | 2020-11-10 | The Trustees Of The University Of Pennsylvania | Methods for improving the efficacy and expansion of immune cells |
| US11667691B2 (en) | 2015-08-07 | 2023-06-06 | Novartis Ag | Treatment of cancer using chimeric CD3 receptor proteins |
| JP6905163B2 (ja) | 2015-09-03 | 2021-07-21 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | サイトカイン放出症候群を予測するバイオマーカー |
| KR20180051625A (ko) | 2015-09-17 | 2018-05-16 | 노파르티스 아게 | 증진된 효능을 갖는 car t 세포 요법 |
| EP3393504A1 (en) | 2015-12-22 | 2018-10-31 | Novartis AG | Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy |
| JP2019500394A (ja) | 2015-12-30 | 2019-01-10 | ノバルティス アーゲー | 有効性が増強された免疫エフェクター細胞治療 |
| US20200281973A1 (en) | 2016-03-04 | 2020-09-10 | Novartis Ag | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore |
| US11549099B2 (en) | 2016-03-23 | 2023-01-10 | Novartis Ag | Cell secreted minibodies and uses thereof |
| ES2944607T3 (es) | 2016-04-15 | 2023-06-22 | Novartis Ag | Composiciones y métodos para la expresión selectiva de receptores quiméricos para el antígeno |
| EP3464375A2 (en) | 2016-06-02 | 2019-04-10 | Novartis AG | Therapeutic regimens for chimeric antigen receptor (car)- expressing cells |
| CA3030837A1 (en) | 2016-07-15 | 2018-01-18 | Novartis Ag | Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor |
| AU2017302668B9 (en) | 2016-07-28 | 2023-06-22 | Novartis Ag | Combination therapies of chimeric antigen receptors and PD-1 inhibitors |
| JP2019527696A (ja) | 2016-08-01 | 2019-10-03 | ノバルティス アーゲー | プロｍ２マクロファージ分子の阻害剤と組み合わせてキメラ抗原受容体を用いる癌の処置 |
| JP2019532953A (ja) | 2016-09-30 | 2019-11-14 | ノバルティス アーゲー | 増強された有効性を有する免疫エフェクター細胞治療 |
| EP3523331A1 (en) | 2016-10-07 | 2019-08-14 | Novartis AG | Chimeric antigen receptors for the treatment of cancer |
| WO2018175733A1 (en) | 2017-03-22 | 2018-09-27 | Novartis Ag | Biomarkers and car t cell therapies with enhanced efficacy |
| US11535662B2 (en) | 2017-01-26 | 2022-12-27 | Novartis Ag | CD28 compositions and methods for chimeric antigen receptor therapy |
| CN110582509A (zh) | 2017-01-31 | 2019-12-17 | 诺华股份有限公司 | 使用具有多特异性的嵌合t细胞受体蛋白治疗癌症 |
| US20200048359A1 (en) | 2017-02-28 | 2020-02-13 | Novartis Ag | Shp inhibitor compositions and uses for chimeric antigen receptor therapy |
| EP3615055A1 (en) | 2017-04-28 | 2020-03-04 | Novartis AG | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
| US20200179511A1 (en) | 2017-04-28 | 2020-06-11 | Novartis Ag | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| JP2021501570A (ja) | 2017-10-18 | 2021-01-21 | ノバルティス アーゲー | 選択的タンパク質分解のための組成物及び方法 |
| RU2020116579A (ru) | 2017-10-25 | 2021-11-25 | Новартис Аг | Способы получения клеток, экспрессирующих химерный антигенный рецептор |
| MX2020004948A (es) | 2017-11-15 | 2020-11-11 | Novartis Ag | Receptor de antígeno quimérico que selecciona como diana bcma, receptor de antígeno quimérico que selecciona como diana cd19 y terapias de combinación. |
| MX2020005651A (es) | 2017-11-30 | 2020-10-28 | Novartis Ag | Receptor de antigeno quimerico dirigido a bcma y usos del mismo. |
| CN112218651A (zh) | 2018-01-08 | 2021-01-12 | 诺华公司 | 用于与嵌合抗原受体疗法组合的免疫增强rna |
| WO2019160956A1 (en) | 2018-02-13 | 2019-08-22 | Novartis Ag | Chimeric antigen receptor therapy in combination with il-15r and il15 |
| US20200061113A1 (en) | 2018-04-12 | 2020-02-27 | Novartis Ag | Chimeric antigen receptor therapy characterization assays and uses thereof |
| WO2019210153A1 (en) | 2018-04-27 | 2019-10-31 | Novartis Ag | Car t cell therapies with enhanced efficacy |
| US20210396739A1 (en) | 2018-05-01 | 2021-12-23 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
| US20200085869A1 (en) | 2018-05-16 | 2020-03-19 | Novartis Ag | Therapeutic regimens for chimeric antigen receptor therapies |
| EP3801769A1 (en) | 2018-05-25 | 2021-04-14 | Novartis AG | Combination therapy with chimeric antigen receptor (car) therapies |
| US20210214459A1 (en) | 2018-05-31 | 2021-07-15 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| CN112203725A (zh) | 2018-06-13 | 2021-01-08 | 诺华股份有限公司 | Bcma嵌合抗原受体及其用途 |
| US20210171909A1 (en) | 2018-08-31 | 2021-06-10 | Novartis Ag | Methods of making chimeric antigen receptor?expressing cells |
| CN112639083A (zh) | 2018-08-31 | 2021-04-09 | 诺华股份有限公司 | 制备表达嵌合抗原受体的细胞的方法 |
| EP3856779A1 (en) | 2018-09-28 | 2021-08-04 | Novartis AG | Cd22 chimeric antigen receptor (car) therapies |
| WO2020069409A1 (en) | 2018-09-28 | 2020-04-02 | Novartis Ag | Cd19 chimeric antigen receptor (car) and cd22 car combination therapies |
| JP2022523204A (ja) | 2019-02-25 | 2022-04-21 | ノバルティス アーゲー | ウイルス送達のためのメソポーラスシリカ粒子組成物 |
| WO2020191316A1 (en) | 2019-03-21 | 2020-09-24 | Novartis Ag | Car-t cell therapies with enhanced efficacy |
| US20220168389A1 (en) | 2019-04-12 | 2022-06-02 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| EP3959320A1 (en) | 2019-04-24 | 2022-03-02 | Novartis AG | Compositions and methods for selective protein degradation |
| AU2020394441A1 (en) | 2019-11-26 | 2022-06-02 | Novartis Ag | CD19 and CD22 chimeric antigen receptors and uses thereof |
| IL293215A (en) | 2019-11-26 | 2022-07-01 | Novartis Ag | Chimeric antigen receptors that bind bcma and cd19 and their uses |
| WO2021163618A1 (en) | 2020-02-14 | 2021-08-19 | Novartis Ag | Method of predicting response to chimeric antigen receptor therapy |
-
2014
- 2014-02-20 WO PCT/US2014/017364 patent/WO2014130657A1/en active Application Filing
- 2014-02-20 RU RU2015139874A patent/RU2708032C2/ru active
- 2014-02-20 RU RU2019137208A patent/RU2019137208A/ru unknown
- 2014-02-20 CN CN201480009507.1A patent/CN105358576B/zh active Active
- 2014-02-20 KR KR1020157025483A patent/KR102313997B1/ko active IP Right Grant
- 2014-02-20 SG SG11201505896YA patent/SG11201505896YA/en unknown
- 2014-02-20 ES ES14713280T patent/ES2760023T3/es active Active
- 2014-02-20 EP EP14713280.7A patent/EP2958943B1/en active Active
- 2014-02-20 PL PL14713280T patent/PL2958943T3/pl unknown
- 2014-02-20 AU AU2014218976A patent/AU2014218976B2/en active Active
- 2014-02-20 EP EP19196212.5A patent/EP3626741A1/en active Pending
- 2014-02-20 MX MX2015010836A patent/MX2015010836A/es active IP Right Grant
- 2014-02-20 BR BR112015019603A patent/BR112015019603A2/pt not_active Application Discontinuation
- 2014-02-20 JP JP2015558946A patent/JP6647868B2/ja active Active
- 2014-02-20 US US14/184,924 patent/US9394368B2/en active Active
- 2014-02-20 DK DK14713280T patent/DK2958943T3/da active
- 2014-02-20 MY MYPI2015702442A patent/MY190711A/en unknown
- 2014-02-20 PT PT147132807T patent/PT2958943T/pt unknown
- 2014-02-20 KR KR1020217032762A patent/KR102509562B1/ko active IP Right Grant
- 2014-02-20 LT LTEP14713280.7T patent/LT2958943T/lt unknown
- 2014-02-20 KR KR1020237008246A patent/KR102685501B1/ko active IP Right Grant
- 2014-02-20 CN CN201911338490.5A patent/CN111139256A/zh active Pending
- 2014-02-20 HU HUE14713280A patent/HUE046961T2/hu unknown
- 2014-02-20 CA CA2901960A patent/CA2901960C/en active Active
-
2015
- 2015-08-03 IL IL24033515A patent/IL240335B/en active IP Right Grant
-
2016
- 2016-05-11 HK HK16105386.3A patent/HK1217498A1/zh unknown
- 2016-06-15 US US15/182,775 patent/US10308717B2/en active Active
-
2019
- 2019-02-15 AU AU2019201075A patent/AU2019201075B2/en active Active
- 2019-04-12 US US16/382,402 patent/US11865167B2/en active Active
- 2019-11-27 JP JP2019214013A patent/JP7189860B2/ja active Active
-
2022
- 2022-09-16 JP JP2022148492A patent/JP2022191241A/ja active Pending
-
2023
- 2023-11-09 US US18/505,864 patent/US20240238396A1/en active Pending
-
2024
- 2024-06-26 JP JP2024102953A patent/JP2024129069A/ja active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7340638B2 (ja) | 2016-06-27 | 2023-09-07 | ジュノー セラピューティクス インコーポレイテッド | Ｍｈｃ－ｅ拘束性エピトープ、結合分子ならびに関連する方法および使用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016508725A5 (ja) | ||
| JP2022191241A5 (ja) | ||
| JP2016514462A5 (ja) | ||
| RU2019137208A (ru) | ЛЕЧЕНИЕ РАКА С ИСПОЛЬЗОВАНИЕМ ХИМЕРНОГО АНТИГЕНСПЕЦИФИЧЕСКОГО РЕЦЕПТОРА НА ОСНОВЕ ГУМАНИЗИРОВАННОГО АНТИТЕЛА ПРОТИВ EGFRvIII | |
| AU2017302668B2 (en) | Combination therapies of chimeric antigen receptors and PD-1 inhibitors | |
| JP2017500869A5 (ja) | ||
| ES2948133T3 (es) | Métodos para mejorar la eficacia y expansión de células que expresan un receptor de antígeno quimérico | |
| AU2017250304B2 (en) | Compositions and methods for selective protein expression | |
| JP2017508466A5 (ja) | ||
| JP2021509009A (ja) | Ｂｃｍａターゲティングキメラ抗原受容体及びその使用 | |
| JP2019537433A5 (ja) | ||
| CA3030837A1 (en) | Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor | |
| RU2016138422A (ru) | Химерный антигенный рецептор | |
| JP2015527070A5 (ja) | ||
| US20200368268A1 (en) | Immune-enhancing rnas for combination with chimeric antigen receptor therapy | |
| JP2014533928A5 (ja) | ||
| RU2015144332A (ru) | Лечение рака с помощью гуманизированного анти-cd19 химерного антигенного рецептора | |
| RU2017121892A (ru) | Клетка | |
| CN114258430A (zh) | 使用融合蛋白进行tcr重编程的组合物和方法 | |
| JP2017527271A5 (ja) | ||
| JP2017524367A5 (ja) | ||
| US20210177951A1 (en) | Engineered cells & methods | |
| CN116829194A (zh) | 用于工程化细胞疗法的靶向细胞因子构建体 | |
| JP2018500337A5 (ja) | ||
| WO2020172553A1 (en) | Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors |